These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 984795)

  • 41. In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli.
    Jorgensen JH; Crawford SA; Alexander GA
    Antimicrob Agents Chemother; 1980 Jun; 17(6):937-42. PubMed ID: 6250470
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhanced in vitro bactericidal activity of amikacin or gentamicin combined with three new extended-spectrum cephalosporins against cephalothin-resistant members of the family Enterobacteriaceae.
    Bayer AS; Eisenstadt R; Morrison JO
    Antimicrob Agents Chemother; 1984 Jun; 25(6):725-8. PubMed ID: 6331297
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cefuroxime, a beta-lactamase-resistant cephalosporin with a broad spectrum of gram-positive and -negative activity.
    Neu HC; Fu KP
    Antimicrob Agents Chemother; 1978 Apr; 13(4):657-64. PubMed ID: 248268
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined action of beta-lactum antibiotics against gram-negative bacilli.
    Bobrowski MM; Gebicka K; Borowski J
    J Hyg Epidemiol Microbiol Immunol; 1973; 17(2):129-40. PubMed ID: 4199760
    [No Abstract]   [Full Text] [Related]  

  • 45. In vitro activity of moxalactam against pathogenic bacteria and its comparison with other antibiotics.
    Perrymann F; Flournoy DJ; Qadri SM
    Chemotherapy; 1983; 29(1):37-42. PubMed ID: 6219865
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Combined in vitro effect of new betalactam antibiotics and aminoglycosides against Pseudomonas aeruginosa ].
    Thabaut A; Durosoir JL; Meyran M
    Pathol Biol (Paris); 1982 Jun; 30(6 Pt 2):549-54. PubMed ID: 6812006
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro evaluation of cefoxitin and cefamandole.
    Adams HG; Stilwell GA; Turck M
    Antimicrob Agents Chemother; 1976 Jun; 9(6):1019-24. PubMed ID: 820241
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Newer beta-lactam antibiotics.
    Hamilton-Miller JM; Brumfitt W
    Infection; 1974; 2(2):82-94. PubMed ID: 4367171
    [No Abstract]   [Full Text] [Related]  

  • 49. Chloramphenicol kills Haemophilus influenzae more rapidly than does ampicillin or cefamandole.
    Schauf V; Green DC; van der Stuyf L; Riff L
    Antimicrob Agents Chemother; 1983 Mar; 23(3):364-8. PubMed ID: 6601927
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro antibacterial activity of a new 1-oxa cephalosporin compound.
    Downs JT; Andriole VT
    Yale J Biol Med; 1980; 53(2):149-59. PubMed ID: 6446810
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Susceptibility of pneumococci to 14 beta-lactam agents: comparison of strains resistant, intermediate-resistant, and susceptible to penicillin.
    Ward JI; Moellering RC
    Antimicrob Agents Chemother; 1981 Aug; 20(2):204-7. PubMed ID: 6912777
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative activity of ampicillin and seven cephalosporins against group D streptococci.
    Hamilton-Miller JM
    J Clin Pathol; 1974 Oct; 27(10):828-31. PubMed ID: 4214839
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [In vitro study of combinations between third-generation cephalosporins and aminoglycosides on Enterobacteriaceae].
    Fosse T; Soussy CJ; Duval J
    Pathol Biol (Paris); 1983 Jun; 31(6):483-7. PubMed ID: 6348654
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aminoglycoside inactivation by penicillins and cephalosporins and its impact on drug-level monitoring.
    Tindula RJ; Ambrose PJ; Harralson AF
    Drug Intell Clin Pharm; 1983 Dec; 17(12):906-8. PubMed ID: 6653408
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cefoxitin activity against multiply antibiotic-resistance Klebsiella pneumoniae in vitro.
    Jackson RT; Thomas FE; Alford RH
    Antimicrob Agents Chemother; 1977 Jan; 11(1):84-7. PubMed ID: 319753
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro activity of LY127935, a new 1-oxa cephalosporin, against aerobic gram-negative bacilli.
    Delgado DG; Brau CJ; Cobbs CG; Dismukes WE
    Antimicrob Agents Chemother; 1979 Dec; 16(6):864-8. PubMed ID: 533267
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibiotic use in neonatal sepsis.
    Yurdakök M
    Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of Antimicrobial Effects of a New Polymyxin Molecule (SPR741) When Tested in Combination with a Series of β-Lactam Agents Against a Challenge Set of Gram-Negative Pathogens.
    Mendes RE; Rhomberg PR; Lister T; Cotroneo N; Rubio A; Flamm RK
    Microb Drug Resist; 2020 Apr; 26(4):319-328. PubMed ID: 31596663
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-content aminoglycoside disks for determining aminoglycoside-penicillin synergy against Enterococcus faecalis.
    Sahm DF; Torres C
    J Clin Microbiol; 1988 Feb; 26(2):257-60. PubMed ID: 3125218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.